4
Changes in Ownership
Alkermes plc. Filed Acc 0001127602-24-028885
EVP R&D, Chief Medical Officer sold 61,151 shares at $32.07 ($1,961,406)
- EVP R&D, Chief Medical Officer acquired 48,997 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Option exercise 10b5-1 | +12,452 | $20.03 | $249,414 | 72,182 | D |
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Option exercise 10b5-1 | +12,090 | $19.34 | $233,821 | 84,272 | D |
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Option exercise 10b5-1 | +12,044 | $24.59 | $296,162 | 96,316 | D |
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Option exercise 10b5-1 | +12,411 | $26.82 | $332,863 | 108,727 | D |
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Sale 10b5-1 | −61,151 | $32.07 | $1,961,406 | 47,576 | D |
| Derivatives | |||||||
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −12,452 | 116,722 | D | ||
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −12,090 | 188,323 | D | ||
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −12,044 | 130,300 | D | ||
| Hopkinson Craig C. EVP R&D, Chief Medical Officer | 2024-12-09 | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −12,411 | 110,616 | D | ||
| Open-market sales · 61,151 sh · avg $32.07 · $1,961,406 | |||||||
Loading xslF345X05/form4.xml…